Therapeutic Solutions International, Inc. Announces Formation of Scientific Advisory Board

Therapeutic Solutions International, Inc. Announces Formation of Scientific 
Advisory Board 
Dr. Barry Glassman Appointed as Chairman 
OCEANSIDE, CA -- (Marketwired) -- 06/11/13 --  Therapeutic Solutions
International, Inc. (OTCQB: TSOI) announced today the creation of a
Scientific Advisory Board with Dr. Barry Glassman appointed as
Dr. Glassman, Vice President of Education and Training for TSI, said,
"Our goal is to attract both clinical and research oriented
professionals to guide product development and utilization. This
Advisory Board will serve to continue our efforts to use evidenced
based concepts in the advancement of the use of already proven
therapy. This will help guide our efforts to educate more health
practitioners, thereby increasing the use of appliance therapy in
general dentistry, the treatment of trigeminally mediated disorders,
as well as the treatment of sleep disturbed breathing." 
Tim Dixon, CEO of TSI, stated, "The new Scientific Advisory Board
will allow TSI management to tap into the expertise of additional
appointees that Dr. Glassman brings to this Board to consider
additional technologies and products that fit within our mission
statement to provide cost effective treatment modalities and
Therapeutic Solutions International is the global manufacturer of the
chairside anterior midpoint stop appliance (AMPSA) devices marketed
internationally under the trade names Migran-X(R) and AMPSA CS(R),
which have helped countless patients prevent debilitating migraine
and tension headache pain, bruxism, clenching, grinding, and TMJ
disorders. The Migran-X(R) and AMPSA CS(R) devices are the most
effective non-drug US FDA cleared dental method of migraine
prevention on the market today.  
About Therapeutic Solutions International, Inc. 
The Company's corporate website is
Non-US dentists and physicians can order our AMPSA products at 
Safe Harbor Statement 
This release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions upon
which they are based are reasonable, we can give no assurance that
such expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect," "anticipate,"
"estimate," "believe," "intend," or "project" or the negative of
these words or other variations on these words or comparable
terminology. The reader is cautioned not to put undue reliance on
these forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our SEC filings. To the extent
that statements in this press release are not strictly historical,
including statements as to revenue projections, business strategy,
outlook, objectives, future milestones, plans, intentions, goals,
future financial conditions, future collaboration agreements, the
success of the Company's development, events conditioned on
stockholder or other approval, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. The forward-looking statements contained in this release are
subject to certain risks and uncertainties that could cause actual
results to differ materially from the statements made. Readers are
advised to review our filings with the Securities and Exchange
Commission that can be accessed over the Internet at the SEC's
website located at 
For more information please contact: 
Therapeutic Solutions International, Inc. 
Press spacebar to pause and continue. Press esc to stop.